Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Immunocore (IMCR) with an Overweight rating and $60 price target The firm believes Kimmtrak “provides a good floor value” for the stock and indication expansion opportunities could offer upside over the next 12 months. There is room for further penetration, especially in the community setting, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore’s Innovative Approach: A New Hope for PRAME-Positive Cancer Treatment
- Immunocore’s Phase 3 Melanoma Study: A Potential Game Changer?
- Immunocore’s Promising Melanoma Study: A Potential Game-Changer
- Immunocore’s Brenetafusp: A Promising Study in PRAME-Positive Cancers
- Immunocore’s Innovative Cancer Study: A Potential Game-Changer for Investors